Picture of Olema Pharmaceuticals logo

OLMA — Olema Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Olema Pharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview

* Olema Pharmaceuticals Inc  OLMA.OQ   OLMA.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 6 (estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Olema Pharmaceuticals
Inc is
for a loss of 55 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Olema
Pharmaceuticals Inc is $29.00​, above​ its last closing price
of $16.46. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.55       -0.55      -0.56     Missed  -2.6
 Dec. 31 2024  -0.48       -0.48      -0.49     Missed  -1.9
 Sep. 30 2023  -0.50       -0.51      -0.48     Beat    6.1​
 Jun. 30 2023  -0.72       -0.73      -0.49     Beat    32.6
 ​​Mar.        -0.71       -0.66      -0.70     Missed  -5.5
 31 2023                                                
 Dec. 31 2022  -0.62       -0.65      -0.65     Met     0.3​
 Sep. 30 2022  -0.76       -0.77      -0.57     Beat    25.8
 Jun. 30 2022  -0.65       -0.64      -0.82     Missed  -27.7
 This summary was machine generated August 2 at 11:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Olema Pharmaceuticals

See all news